Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
Industry leader with global clinical development expertise to help guide Imara’s clinical advancement
Imara also announces departure of Chief Medical Officer,
“We are fortunate to have the benefit of Ed’s clinical leadership expertise and insights on our Board,” said
“Joining Imara’s Board at such an exciting point in the Company’s evolution is a responsibility I take very seriously,” said
Imara also announced today that its Chief Medical Officer,
“On behalf of everyone at Imara, I’d like to thank Wim for his many contributions to our clinical development program over the past year and more broadly, for over 25 years of service in the pharma and biotech industry. We wish him all the best in the next phase of his career,” said
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company’s plans, strategies and prospects. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s prospectus filed with the
Source: Imara, Inc.